2017 Practical Management of Metastatic Prostate Cancer: Guidelines and Beyond Webcast
Course InformationAccess Materials Overview
Urologists continue to indicate one of the greatest educational needs in treating CRPC patients is the sequencing of agents. With the numerous new treatments now available to urologists to manage the CRPC patient, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy. Urologists play a central role in the management of metastatic and castrate resistant prostate cancer and as their role continues to increase, knowledge of the various side effects of the numerous treatments that are available is paramount.
This course will provide essential information on the role of systemic therapy in the treatment of metastatic prostate cancer, focusing upon a thorough review of the AUA CRPC Guidelines, followed by management of castrate sensitive prostate cancer with systemic agents, sequencing of agents, managing side effects of treatments, management of comorbid conditions, and identifying potential interactions between agents. Additionally, the course will include a section on pain management and training on counseling/support of patients in end-of-life issues.
After attending this course, participants should be able to:
- Apply the AUA CRPC Guidelines for FDA approved agents in the management of CRPC and optimization of the AUA algorithm for patient clinical benefit.
- Evaluate and diagnose CRPC patients and discuss the sequencing and combinatorial treatment strategies from both clinical and administrative perspectives.
- Analyze the role of systemic agents in androgen sensitive metastatic prostate cancer.
- Examine the side effect profiles and potential interactions of various therapeutic strategies for CRPC.
- Oversee comorbid conditions and describe their management in the context of CRPC treatment.
- Manage both the acute and chronic pain that is inherent in the care of CRPC patients.
- Communicate the pertinent end-of-life issues that surround CRPC patients and their families.
- All providers who are involved in the care of CRPC, including urologists, medical oncologists, radiation oncologists, advanced practice providers (e.g. ARNP, PA), and nursing staff.
The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:
Tolmar Pharmaceuticals, Inc.
AUAER ensures that all educational activities are developed and implemented independent of the control and/or influence of any commercial interests (ACCME: SCS1)